Home>Healthcare>Medical Devices and Medical Diagnosis

Medical Devices and Medical Diagnosis

During the Reporting Period, the Group recorded revenue of RMB5,208 million from the medical devices and medical diagnosis segment, representing a year-on-year increase of 39.70%; segment results amounted to RMB1,053 million, which increased by 83.45% year-on-year; segment profit amounted to RMB907 million, which increased by 83.23% year-on-year. The year-on-year increase in sales revenue and net profit were mainly attributable to the contributions from the anti-pandemic products (e.g. the nucleic acid test kits for 2019-nCoV, negative pressure ambulances and ventilators), and the resumption of our conventional businesses.

Medical Devices

  • During the Reporting Period, the Group promptly launched anti-pandemic products and carried out global procurement of pandemic supplies, to support pandemic prevention and control at home and abroad. In order to meet the need for the treatment of COVID-19 pandemic, the Group responded quickly and provided material logistics for the prevention and control of the pandemic, including undertaking the production task of negative pressure ambulances, further expanded the production capacity of ventilators to ensure the global supply of ventilators, and ensured the supply of portable full body CT scanners, reducing the risk of cross-infection in multiple departments caused by patient transfer.
  • During the Reporting Period, Sisram Medical continued to develop the global market (especially the emerging markets), and strengthened its new product portfolio, in particular, by increasing R&D expenditure in minimally invasive treatment systems. Its four new products launched in 2020, namely Derma Clear, Harmony XL Pro, Opus Plasma (North America version) and Alma Hybrid received extensive attention and positive responses from the market.
  • the number of installation of, and the volume of surgeries in respect of, the Da Vinci surgical robotic system of the joint ventures Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd.* (直觀復星醫療器械技術(上海) 有限公司) (‘‘Intuitive Fosun (Shanghai)’’) and Intuitive Surgical-Fosun (Hongkong) Co., Limited ("Intuitive Fosun (HK)") has recovered rapidly since the second quarter. In 2020, 55 Da Vinci surgical robotic systems were installed, and the volume of surgeries grew continuously.

Medical Diagnosis

  • The independently developed nucleic acid test kits for 2019-nCoV (Fluorescent PCR Method) obtained emergency approval from the NMPA and registration certificates for medical devices (in-vitro diagnostic reagents). Certain nucleic acid test kits for 2019-nCoV also obtained relevant qualifications and certifications in certain countries and regions, including the U.S., the EU and Australia.

Subsidiaries

Joint-venture Enterprises

About other business of Fosun Pharma